EyePoint's DURAVYU misses primary endpoint in LUCIA Phase 3 wet AMD trial

EyePoint announced topline results from LUCIA, the second pivotal Phase 3 trial of DURAVYU (vorolanib intravitreal insert) in wet age-related macular degeneration, which did not achieve the primary endpoint.

Detected & updated continuously · Source: Nebula